E
Ainos, Inc.
AIMD
$0.4852
-$0.006-1.22%
E
Sell
1/4/2024Downgrade
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index.
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index.
D
Sell
12/15/2023Upgraded
Ainos, Inc. (AIMD) was upgraded to D- from E+ on 12/15/2023 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 1.23 to 2.89, and operating cash flow increased 35.42% from -$1.15M to -$743.3.
Ainos, Inc. (AIMD) was upgraded to D- from E+ on 12/15/2023 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 1.23 to 2.89, and operating cash flow increased 35.42% from -$1.15M to -$743.3.
E
Sell
10/17/2023Downgrade
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 10/17/2023 due to a decline in the volatility index.
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 10/17/2023 due to a decline in the volatility index.
D
Sell
5/25/2023Upgraded
Ainos, Inc. (AIMD) was upgraded to D- from E+ on 5/25/2023 due to an increase in the volatility index and total return index.
Ainos, Inc. (AIMD) was upgraded to D- from E+ on 5/25/2023 due to an increase in the volatility index and total return index.
E
Sell
5/8/2023Downgrade
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 5/8/2023 due to a decline in the volatility index.
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 5/8/2023 due to a decline in the volatility index.
D
Sell
4/21/2023Upgraded
Ainos, Inc. (AIMD) was upgraded to D- from E+ on 4/21/2023 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.5112 to -$0.1069, EBIT increased 72.81% from -$7.82M to -$2.13M, and operating cash flow increased 21.76% from -$786.6 to -$615.4.
Ainos, Inc. (AIMD) was upgraded to D- from E+ on 4/21/2023 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.5112 to -$0.1069, EBIT increased 72.81% from -$7.82M to -$2.13M, and operating cash flow increased 21.76% from -$786.6 to -$615.4.
E
Sell
3/14/2023Downgrade
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
Ainos, Inc. (AIMD) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
Ainos, Inc. (AIMD) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index.
Ainos, Inc. (AIMD) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index.
D
Sell
11/21/2022Downgrade
Ainos, Inc. (AIMD) was downgraded to D- from D on 11/21/2022 due to a substantial decline in the total return index, volatility index and growth index. EBIT declined 302.32% from -$1.94M to -$7.82M, operating cash flow declined 243.04% from -$229.3 to -$786.6, and earnings per share declined from -$0.203 to -$0.5112.
Ainos, Inc. (AIMD) was downgraded to D- from D on 11/21/2022 due to a substantial decline in the total return index, volatility index and growth index. EBIT declined 302.32% from -$1.94M to -$7.82M, operating cash flow declined 243.04% from -$229.3 to -$786.6, and earnings per share declined from -$0.203 to -$0.5112.
D
Sell
5/16/2022Upgraded
Ainos, Inc. (AIMD) was upgraded to D from E+ on 05/16/2022.
Ainos, Inc. (AIMD) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Ainos, Inc. (AIMD) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
Ainos, Inc. (AIMD) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
Ainos, Inc. (AIMD) was upgraded to D from E+ on 05/04/2022.
Ainos, Inc. (AIMD) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Ainos, Inc. (AIMD) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Ainos, Inc. (AIMD) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Ainos, Inc. (AIMD) was upgraded to D from E+ on 04/21/2022.
Ainos, Inc. (AIMD) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Ainos, Inc. (AIMD) was downgraded to E+ from D on 4/20/2022 due to a major decline in the solvency index and valuation index. Debt to equity increased from 0.13 to 0.35, and the quick ratio declined from 0.27 to 0.06.
Ainos, Inc. (AIMD) was downgraded to E+ from D on 4/20/2022 due to a major decline in the solvency index and valuation index. Debt to equity increased from 0.13 to 0.35, and the quick ratio declined from 0.27 to 0.06.
D
Sell
11/22/2021Upgraded
Ainos, Inc. (AIMD) was upgraded to D from D- on 11/22/2021 due to an increase in the solvency index and valuation index.
Ainos, Inc. (AIMD) was upgraded to D from D- on 11/22/2021 due to an increase in the solvency index and valuation index.
D
Sell
11/8/2021Downgrade
Ainos, Inc. (AIMD) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Ainos, Inc. (AIMD) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
8/31/2020Upgraded
Amarillo Biosciences, Inc. (AMAR) was upgraded to D from D- on 8/31/2020 due to a large increase in the growth index.
Amarillo Biosciences, Inc. (AMAR) was upgraded to D from D- on 8/31/2020 due to a large increase in the growth index.
D
Sell
8/14/2020Downgrade
Amarillo Biosciences, Inc. (AMAR) was downgraded to D- from D on 8/14/2020 due to a noticeable decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.33 to 0.2, and debt to equity increased from -1.18 to -1.06.
Amarillo Biosciences, Inc. (AMAR) was downgraded to D- from D on 8/14/2020 due to a noticeable decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.33 to 0.2, and debt to equity increased from -1.18 to -1.06.
D
Sell
5/1/2020Upgraded
Amarillo Biosciences, Inc. (AMAR) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index and growth index.
Amarillo Biosciences, Inc. (AMAR) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index and growth index.
D
Sell
4/1/2020Upgraded
Amarillo Biosciences, Inc. (AMAR) was upgraded to D- from E+ on 4/1/2020 due to a noticeable increase in the valuation index, solvency index and efficiency index. Debt to equity declined from 4.76 to -2.84.
Amarillo Biosciences, Inc. (AMAR) was upgraded to D- from E+ on 4/1/2020 due to a noticeable increase in the valuation index, solvency index and efficiency index. Debt to equity declined from 4.76 to -2.84.
E
Sell
2/26/2020Downgrade
Amarillo Biosciences, Inc. (AMAR) was downgraded to E+ from D- on 2/26/2020 due to a large decline in the total return index, volatility index and growth index.
Amarillo Biosciences, Inc. (AMAR) was downgraded to E+ from D- on 2/26/2020 due to a large decline in the total return index, volatility index and growth index.
D
Sell
11/14/2019Downgrade
Amarillo Biosciences, Inc. (AMAR) was downgraded to D- from D on 11/14/2019 due to a large decline in the solvency index and valuation index. Debt to equity increased from 1.99 to 4.76, and the quick ratio declined from 1.03 to 0.79.
Amarillo Biosciences, Inc. (AMAR) was downgraded to D- from D on 11/14/2019 due to a large decline in the solvency index and valuation index. Debt to equity increased from 1.99 to 4.76, and the quick ratio declined from 1.03 to 0.79.
D
Sell
8/13/2019Upgraded
Amarillo Biosciences, Inc. (AMAR) was upgraded to D from D- on 8/13/2019 due to a large increase in the solvency index, total return index and volatility index.
Amarillo Biosciences, Inc. (AMAR) was upgraded to D from D- on 8/13/2019 due to a large increase in the solvency index, total return index and volatility index.
D
Sell
5/24/2018Downgrade
Amarillo Biosciences, Inc. (AMAR) was downgraded to D- from D on 5/24/2018 due to a noticeable decline in the efficiency index, total return index and valuation index.
Amarillo Biosciences, Inc. (AMAR) was downgraded to D- from D on 5/24/2018 due to a noticeable decline in the efficiency index, total return index and valuation index.
D
Sell
11/21/2017Downgrade
Amarillo Biosciences, Inc. (AMAR) was downgraded to D from D+ on 11/21/2017 due to a large decline in the total return index, growth index and solvency index. Earnings per share declined from $0.0006 to -$0.0102, EBIT declined 1,660.14% from $14.8 to -$230.9, and debt to equity increased from -0.99 to -0.91.
Amarillo Biosciences, Inc. (AMAR) was downgraded to D from D+ on 11/21/2017 due to a large decline in the total return index, growth index and solvency index. Earnings per share declined from $0.0006 to -$0.0102, EBIT declined 1,660.14% from $14.8 to -$230.9, and debt to equity increased from -0.99 to -0.91.
D
Sell
10/12/2017Downgrade
Amarillo Biosciences, Inc. (AMAR) was downgraded to D+ from C- on 10/12/2017 due to a decline in the total return index.
Amarillo Biosciences, Inc. (AMAR) was downgraded to D+ from C- on 10/12/2017 due to a decline in the total return index.
C
Hold
8/11/2017Upgraded
Amarillo Biosciences, Inc. (AMAR) was upgraded to C- from D+ on 8/11/2017 due to a noticeable increase in the growth index. EBIT increased 108% from -$185 to $14.8, earnings per share increased from -$0.0085 to $0.0006, and operating cash flow increased 73.83% from -$126.5 to -$33.1.
Amarillo Biosciences, Inc. (AMAR) was upgraded to C- from D+ on 8/11/2017 due to a noticeable increase in the growth index. EBIT increased 108% from -$185 to $14.8, earnings per share increased from -$0.0085 to $0.0006, and operating cash flow increased 73.83% from -$126.5 to -$33.1.
D
Sell
8/2/2017Downgrade
Amarillo Biosciences, Inc. (AMAR) was downgraded to D+ from C- on 8/2/2017 due to a large decline in the total return index.
Amarillo Biosciences, Inc. (AMAR) was downgraded to D+ from C- on 8/2/2017 due to a large decline in the total return index.
C
Hold
7/18/2017Upgraded
Amarillo Biosciences, Inc. (AMAR) was upgraded to C- from D+ on 7/18/2017 due to a major increase in the total return index and volatility index.
Amarillo Biosciences, Inc. (AMAR) was upgraded to C- from D+ on 7/18/2017 due to a major increase in the total return index and volatility index.
D
Sell
6/30/2017Upgraded
Amarillo Biosciences, Inc. (AMAR) was upgraded to D+ from D on 6/30/2017 due to a major increase in the total return index and volatility index.
Amarillo Biosciences, Inc. (AMAR) was upgraded to D+ from D on 6/30/2017 due to a major increase in the total return index and volatility index.
D
Sell
6/6/2017Downgrade
Amarillo Biosciences, Inc. (AMAR) was downgraded to D from D+ on 6/6/2017 due to a significant decline in the efficiency index and solvency index. Total capital declined 521.2% from -$18.4 to -$114.3, the quick ratio declined from 0.11 to 0.04, and debt to equity increased from -0.98 to -0.87.
Amarillo Biosciences, Inc. (AMAR) was downgraded to D from D+ on 6/6/2017 due to a significant decline in the efficiency index and solvency index. Total capital declined 521.2% from -$18.4 to -$114.3, the quick ratio declined from 0.11 to 0.04, and debt to equity increased from -0.98 to -0.87.
D
Sell
4/18/2017Upgraded
Amarillo Biosciences, Inc. (AMAR) was upgraded to D+ from D on 4/18/2017 due to a significant increase in the efficiency index, growth index and volatility index. Operating cash flow increased 7.95% from -$101.9 to -$93.8.
Amarillo Biosciences, Inc. (AMAR) was upgraded to D+ from D on 4/18/2017 due to a significant increase in the efficiency index, growth index and volatility index. Operating cash flow increased 7.95% from -$101.9 to -$93.8.
D
Sell
11/22/2016Upgraded
Amarillo Biosciences Inc. (AMAR) was upgraded to D from D- on 11/22/2016 due to an increase in the total return index, volatility index and valuation index.
Amarillo Biosciences Inc. (AMAR) was upgraded to D from D- on 11/22/2016 due to an increase in the total return index, volatility index and valuation index.
D
Sell
8/19/2016Downgrade
Amarillo Biosciences Inc. (AMAR) was downgraded to D- from D on 8/19/2016 due to a substantial decline in the growth index, total return index and valuation index. Operating cash flow declined 19,323.53% from $1.7 to -$326.8, EBIT declined 11.38% from -$121.3 to -$135.1, and earnings per share declined from -$0.006 to -$0.0065.
Amarillo Biosciences Inc. (AMAR) was downgraded to D- from D on 8/19/2016 due to a substantial decline in the growth index, total return index and valuation index. Operating cash flow declined 19,323.53% from $1.7 to -$326.8, EBIT declined 11.38% from -$121.3 to -$135.1, and earnings per share declined from -$0.006 to -$0.0065.
D
Sell
5/18/2016Downgrade
Amarillo Biosciences Inc. (AMAR) was downgraded to D from D+ on 5/18/2016 due to a significant decline in the efficiency index and solvency index.
Amarillo Biosciences Inc. (AMAR) was downgraded to D from D+ on 5/18/2016 due to a significant decline in the efficiency index and solvency index.
D
Sell
4/1/2016Downgrade
Amarillo Biosciences Inc. (AMAR) was downgraded to D+ from C on 4/1/2016 due to a significant decline in the valuation index, growth index and solvency index. Operating cash flow declined 334.4% from $118.3 to -$277.3, earnings per share declined from -$0.0057 to -$0.0137, and the quick ratio declined from 0.35 to 0.04.
Amarillo Biosciences Inc. (AMAR) was downgraded to D+ from C on 4/1/2016 due to a significant decline in the valuation index, growth index and solvency index. Operating cash flow declined 334.4% from $118.3 to -$277.3, earnings per share declined from -$0.0057 to -$0.0137, and the quick ratio declined from 0.35 to 0.04.
C
Hold
3/11/2016Downgrade
Amarillo Biosciences Inc. (AMAR) was downgraded to C from B on 3/11/2016 due to a significant decline in the volatility index and total return index.
Amarillo Biosciences Inc. (AMAR) was downgraded to C from B on 3/11/2016 due to a significant decline in the volatility index and total return index.
B
Buy
11/30/2015Upgraded
Amarillo Biosciences Inc. (AMAR) was upgraded to B from B- on 11/30/2015 due to an increase in the growth index.
Amarillo Biosciences Inc. (AMAR) was upgraded to B from B- on 11/30/2015 due to an increase in the growth index.
B
Buy
11/13/2015Downgrade
Amarillo Biosciences Inc. (AMAR) was downgraded to B- from B on 11/13/2015 due to a decline in the efficiency index and growth index. Operating cash flow declined 188.02% from -$134.4 to $118.3, and total capital declined 24.19% from $138.9 to $105.3.
Amarillo Biosciences Inc. (AMAR) was downgraded to B- from B on 11/13/2015 due to a decline in the efficiency index and growth index. Operating cash flow declined 188.02% from -$134.4 to $118.3, and total capital declined 24.19% from $138.9 to $105.3.
B
Buy
10/30/2015Upgraded
Amarillo Biosciences Inc. (AMAR) was upgraded to B from B- on 10/30/2015 due to a noticeable increase in the volatility index.
Amarillo Biosciences Inc. (AMAR) was upgraded to B from B- on 10/30/2015 due to a noticeable increase in the volatility index.
B
Buy
10/8/2015Downgrade
Amarillo Biosciences Inc. (AMAR) was downgraded to B- from B on 10/8/2015 due to a substantial decline in the volatility index and total return index.
Amarillo Biosciences Inc. (AMAR) was downgraded to B- from B on 10/8/2015 due to a substantial decline in the volatility index and total return index.
B
Buy
8/21/2015Upgraded
Amarillo Biosciences Inc. (AMAR) was upgraded to B from B- on 8/21/2015 due to an increase in the total return index, solvency index and growth index. Operating cash flow increased 84.11% from -$73 to -$134.4, and debt to equity declined from -2.69 to -1.57.
Amarillo Biosciences Inc. (AMAR) was upgraded to B from B- on 8/21/2015 due to an increase in the total return index, solvency index and growth index. Operating cash flow increased 84.11% from -$73 to -$134.4, and debt to equity declined from -2.69 to -1.57.
B
Buy
7/21/2015Upgraded
Amarillo Biosciences Inc. (AMAR) was upgraded to B- from C+ on 7/21/2015 due to an increase in the total return index, solvency index and growth index. Debt to equity declined from -12.53 to -2.69.
Amarillo Biosciences Inc. (AMAR) was upgraded to B- from C+ on 7/21/2015 due to an increase in the total return index, solvency index and growth index. Debt to equity declined from -12.53 to -2.69.
C
Hold
4/21/2015Upgraded
Amarillo Biosciences Inc. (AMAR) was upgraded to C+ from C on 4/21/2015 due to a significant increase in the valuation index, solvency index and volatility index. The quick ratio increased from 0 to 1.05.
Amarillo Biosciences Inc. (AMAR) was upgraded to C+ from C on 4/21/2015 due to a significant increase in the valuation index, solvency index and volatility index. The quick ratio increased from 0 to 1.05.
C
Hold
2/4/2015Downgrade
Amarillo Biosciences Inc. (AMAR) was downgraded to C from C+ on 2/4/2015 due to a decline in the total return index.
Amarillo Biosciences Inc. (AMAR) was downgraded to C from C+ on 2/4/2015 due to a decline in the total return index.
C
Hold
1/20/2015Upgraded
Amarillo Biosciences Inc. (AMAR) was upgraded to C+ from C on 1/20/2015 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 4.93% from -$73 to -$76.6.
Amarillo Biosciences Inc. (AMAR) was upgraded to C+ from C on 1/20/2015 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 4.93% from -$73 to -$76.6.
C
Hold
5/30/2014Upgraded
Amarillo Biosciences Inc. (AMARQ) was upgraded to C from C- on 5/30/2014 due to a substantial increase in the valuation index and growth index. Earnings per share increased from -$0.0018 to -$0.0025, and EBIT increased 10.69% from -$158.1 to -$175.
Amarillo Biosciences Inc. (AMARQ) was upgraded to C from C- on 5/30/2014 due to a substantial increase in the valuation index and growth index. Earnings per share increased from -$0.0018 to -$0.0025, and EBIT increased 10.69% from -$158.1 to -$175.
C
Hold
4/16/2014Downgrade
Amarillo Biosciences Inc. (AMARQ) was downgraded to C- from C on 4/16/2014 due to a major decline in the growth index.
Amarillo Biosciences Inc. (AMARQ) was downgraded to C- from C on 4/16/2014 due to a major decline in the growth index.
NASDAQ
04/01/2025 3:52PM Eastern
Quotes delayed
